Dolutegravir for second-line treatment: programmatic implications of new evidence. Zhao, Y., Maartens, G., & Meintjes, G. A Southern African Journal of HIV Medicine, 23(1):a1428, sep, 2022.
Dolutegravir for second-line treatment: programmatic implications of new evidence [link]Paper  doi  bibtex   
@article{Zhao2022,
author = {Zhao, Ying and Maartens, Gary and Meintjes, Graeme A},
doi = {10.4102/SAJHIVMED.V23I1.1428},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhao, Maartens, Meintjes - 2022 - Dolutegravir for second-line treatment programmatic implications of new evidence.pdf:pdf},
issn = {2078-6751},
journal = {Southern African Journal of HIV Medicine},
keywords = {OA,editorial,fund{\_}not{\_}ack},
mendeley-tags = {OA,editorial,fund{\_}not{\_}ack},
month = {sep},
number = {1},
pages = {a1428},
title = {{Dolutegravir for second-line treatment: programmatic implications of new evidence}},
url = {https://sajhivmed.org.za/index.php/hivmed/article/view/1428},
volume = {23},
year = {2022}
}

Downloads: 0